

FORM PTO-1619A  
Expires 06/30/99  
OMB 0651-0027

01-12-1999

U.S. Department of Commerce  
Patent and Trademark Office  
**PATENT**



100939067

# **RECORDATION FORM COVER SHEET PATENTS ONLY**

TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

## Submission Type

- ☒ New
- ☐ Resubmission (Non-Recordation)  
Document ID#
- ☐ Correction of PTO Error  
Reel #  Frame #
- ☐ Corrective Document  
Reel #  Frame #

## Conveyance Type

- ☐ Assignment ☐ Security Agreement
- ☐ License ☐ Change of Name
- ☐ Merger ☒ Other
- U.S. Government**  
(For Use ONLY by U.S. Government Agencies)
- ☒ Departmental File ☐ Secret File

## Conveying Party(ies)

☐ Mark if additional names of conveying parties attached

Name (line 1)  Execution Date  
Month Day Year  
3/24/98

Name (line 2)

## Second Party

Execution Date  
Month Day Year

Name (line 1)

Name (line 2)

## Receiving Party

☐ Mark if additional names of receiving parties attached

Name (line 1)

Name (line 2)

Address (line 1)

Address (line 2)

Address (line 3)     
City State/Country Zip Code

☐ If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment.)

## Domestic Representative Name and Address

Enter for the first Receiving Party only.

Name

Address (line 1)

Address (line 2)

Address (line 3)

Address (line 4)

FOR OFFICE USE ONLY

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS

Mail documents to be recorded with required cover sheet(s) information to  
Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

**PATENT**  
**REEL: 9690 FRAME: 0009**

MD 10-29-98

FORM PTO-1619B

Expires 06/30/99  
OMB 0651-0027

Page 2

U.S. Department of Commerce  
Patent and Trademark Office  
**PATENT****Correspondent Name and Address**Area Code and Telephone Number **301-435-1986**Name **National Institutes of Health, The**Address (line 1) **Extramural Inventions Office, The**Address (line 2) **6701 Rockledge Drive, Room 3188**Address (line 3) **MSC 7750**Address (line 4) **Bethesda, Maryland / USA 20892-7750****Pages**Enter the total number of pages of the attached conveyance document  
including any attachments.# **4****Application Number(s) or Patent Number(s)**☐ Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

**Patent Application Number(s)****08485314****08094510****08503062****08006243****08023953****07832667****08849276****08344080****Patent Number(s)**If this document is being filed together with a new Patent Application, enter the date the patent application was  
signed by the first named executing inventor.

Month Day Year

**Patent Cooperation Treaty (PCT)**Enter PCT application number  
only if a U.S. Application Number  
has not been assigned.

PCT

PCT

PCT

PCT

PCT

PCT

**Number of Properties**

Enter the total number of properties involved.

# **18****Fee Amount**

Fee Amount for Properties Listed (37 CFR 3.41): \$

Method of Payment:  
Deposit AccountEnclosed ☐Deposit Account ☐

(Enter for payment by deposit account or if additional fees can be charged to the account.)

Deposit Account Number:

#

Authorization to charge additional fees:

Yes ☐No ☒**Statement and Signature***To the best of my knowledge and belief, the foregoing information is true and correct and any  
attached copy is a true copy of the original document. Charges to deposit account are authorized, as  
indicated herein.*

Belen Awetahegne

Name of Person Signing

Signature

12/29/98

Date

CONFIRMATORY LICENSE TO THE UNITED STATES GOVERNMENT

RE: Our references: UMMC 93-20  
Invention Title: Schedule Dependent Marrow Transplantation  
U.S. Patent Applications:  
08/849,276 filed 08/25/1997; CIP of  
08/344,080 filed 11/23/94, US Patent No. 5,665,350 issued 09/09/1997  
Funding reference: DK27424  
Lead Inventor: Peter Quesenberry  
Disclosure date: 07/14/1993


The invention referenced above is a Subject Invention, as defined under 35 USC 200, et seq., and the Standard Patent Rights clause in 37 CFR 401.14 or FAR 52.227-11, which are included among the terms of the above-identified grant/contract award from the National Institutes of Health.

This document is confirmatory of:

- 1.) The non-exclusive, non-transferable, irrevocable, paid-up license granted to the Federal Government in the invention described above and in the patent application(s) and any and all divisions, continuations, and continuations-in-part, and in any and all patents and re-issuances thereon; and
- 2.) All other rights acquired by the Government by reason of the above-identified grant/contract award and the laws and regulations which are applicable thereto.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this day, March 24, 1998.



Mr. Michael W. Henry  
Director, Licensing and Ventures  
University of Massachusetts Medical Center

CONFIRMATORY LICENSE TO THE UNITED STATES GOVERNMENT

RE: Our references: UMMC 93-19  
Invention Title: Detection of Individual Gene Transcription and Splicing  
U.S. Patent Applications:  
08/023,953 filed 02/26/1993, US Patent No. 5,563,033 issued 10/08/1996;  
CIP of 07/832,667, previously reported (our reference UMMC 88-01)  
Funding reference: HG00251  
Lead Inventor: Jeanne Lawrence  
Disclosure date: 02/26/1993


The invention referenced above is a Subject Invention, as defined under 35 USC 200, et seq., and the Standard Patent Rights clause in 37 CFR 401.14 or FAR 52.227-11, which are included among the terms of the above-identified grant/contract award from the National Institutes of Health.

This document is confirmatory of:

- 1.) The non-exclusive, non-transferable, irrevocable, paid-up license granted to the Federal Government in the invention described above and in the patent application(s) and any and all divisions, continuations, and continuations-in-part, and in any and all patents and re-issuances thereon; and
- 2.) All other rights acquired by the Government by reason of the above-identified grant/contract award and the laws and regulations which are applicable thereto.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this day, March 24, 1998.



Mr. Michael W. Henry  
Director, Licensing and Ventures  
University of Massachusetts Medical Center

CONFIRMATORY LICENSE TO THE UNITED STATES GOVERNMENT

RE: Our references: UMMC 93-12  
Invention Title: Novel Nuclear Kinase in Signal Transduction  
U.S. Patent Applications:  
08/503,062 filed 07/10/1995, US Patent No. 5,723,300 issued 03/03/1998;  
CIP of 08/006,243 filed 01/19/1993, ABANDONED  
Funding reference: AI07272  
Lead Inventor: Michael R. Green  
Disclosure date: 01/08/1993


The invention referenced above is a Subject Invention, as defined under 35 USC 200, et seq., and the Standard Patent Rights clause in 37 CFR 401.14 or FAR 52.227-11, which are included among the terms of the above-identified grant/contract award from the National Institutes of Health.

This document is confirmatory of:

- 1.) The non-exclusive, non-transferable, irrevocable, paid-up license granted to the Federal Government in the invention described above and in the patent application(s) and any and all divisions, continuations, and continuations-in-part, and in any and all patents and re-issuances thereon; and
- 2.) All other rights acquired by the Government by reason of the above-identified grant/contract award and the laws and regulations which are applicable thereto.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this day, March 24, 1998.



Mr. Michael W. Henry  
Director, Licensing and Ventures  
University of Massachusetts Medical Center

CONFIRMATORY LICENSE TO THE UNITED STATES GOVERNMENT

RE: Our references: UMMC 93-06  
Invention Title: In Vivo Nucleic Acid Hybridization  
U.S. Patent Applications:  
08/485,314 filed 06/07/1995, US Patent No. 5,728,527 issued 03/17/1998;  
CIP of 08/094,510 filed 07/20/1993, ABANDONED  
Funding reference: HB67022  
Lead Inventor: Robert Singer  
Disclosure date: 11/29/1992


The invention referenced above is a Subject Invention, as defined under 35 USC 200, et seq., and the Standard Patent Rights clause in 37 CFR 401.14 or FAR 52.227-11, which are included among the terms of the above-identified grant/contract award from the National Institutes of Health.

This document is confirmatory of:

- 1.) The non-exclusive, non-transferable, irrevocable, paid-up license granted to the Federal Government in the invention described above and in the patent application(s) and any and all divisions, continuations, and continuations-in-part, and in any and all patents and re-issuances thereon; and
- 2.) All other rights acquired by the Government by reason of the above-identified grant/contract award and the laws and regulations which are applicable thereto.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this day, March 24, 1998.



Mr. Michael W. Henry  
Director, Licensing and Ventures  
University of Massachusetts Medical Center